Publication bias and outcome reporting bias: agomelatine as a case example
- PMID: 21846075
- DOI: 10.3928/02793695-20110809-01
Publication bias and outcome reporting bias: agomelatine as a case example
Abstract
Publication bias and outcome reporting bias contribute to distorted perceptions of drug efficacy and the underreporting of adverse events. To demonstrate these biases, this article describes how the clinical profile of the antidepressant agent agomelatine (Valdoxan(®)) has been presented in the literature. Agomelatine has been systematically assessed in 10 short-term placebo-controlled studies and three long-term placebo-controlled relapse prevention studies. Five published trials demonstrated clinically modest but statistically significant benefits over placebo. Five unpublished trials did not find agomelatine more effective than placebo, but in two of these studies the active comparison drug (fluoxetine [Prozac(®)] or paroxetine [Paxil(®)]) was more effective than placebo. Agomelatine was more effective than placebo in one of three relapse prevention studies, but only the positive study was published. Based on what is evident in the entire published and unpublished dataset, agomelatine does not have a tremendously superior sleep and sexual effects profile. The risk of liver toxicity is also not prominently highlighted in the published literature.
Copyright 2011, SLACK Incorporated.
Similar articles
-
A benefit-risk assessment of agomelatine in the treatment of major depression.Drug Saf. 2011 Sep 1;34(9):709-31. doi: 10.2165/11593960-000000000-00000. Drug Saf. 2011. PMID: 21830835 Review.
-
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.Br J Psychiatry. 2013 Sep;203(3):179-87. doi: 10.1192/bjp.bp.112.120196. Br J Psychiatry. 2013. PMID: 23999482 Review.
-
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies.BMJ. 2014 Mar 19;348:g1888. doi: 10.1136/bmj.g1888. BMJ. 2014. PMID: 24647162 Free PMC article. Review.
-
Antidepressant efficacy of Agomelatine: Meta-analysis of placebo controlled and active comparator studies.Asian J Psychiatr. 2021 Nov;65:102866. doi: 10.1016/j.ajp.2021.102866. Epub 2021 Sep 20. Asian J Psychiatr. 2021. PMID: 34592623 Review.
-
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.J Clin Psychiatry. 2007 Nov;68(11):1723-32. doi: 10.4088/jcp.v68n1112. J Clin Psychiatry. 2007. PMID: 18052566 Clinical Trial.
Cited by
-
Clinical trials registries are underused in the pregnancy and childbirth literature: a systematic review of the top 20 journals.BMC Res Notes. 2016 Oct 21;9(1):475. doi: 10.1186/s13104-016-2280-3. BMC Res Notes. 2016. PMID: 27769265 Free PMC article. Review.
-
Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks.Curr Neuropharmacol. 2014 Sep;12(5):287-398. doi: 10.2174/1570159X12999140619122914. Curr Neuropharmacol. 2014. PMID: 25426008 Free PMC article.
-
Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?Neuropsychiatr Dis Treat. 2014 May 20;10:907-14. doi: 10.2147/NDT.S63459. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 24899809 Free PMC article.
-
The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.Int J Mol Sci. 2013 Jun 13;14(6):12458-83. doi: 10.3390/ijms140612458. Int J Mol Sci. 2013. PMID: 23765220 Free PMC article. Review.
-
Publication bias, with a focus on psychiatry: causes and solutions.CNS Drugs. 2013 Jun;27(6):457-68. doi: 10.1007/s40263-013-0067-9. CNS Drugs. 2013. PMID: 23696308 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
